Our study had 3 of 14 eyes (21.4%) develop posterior segment NV in the form of vitreous hemorrhage (VH) or NVD, at 17.8, 30.0, and 11.9 months after symptom onset, despite anti-VEGF treatment. This evidence concerns the gene VEGFA and vitreous hemorrhage.